Instalab
logoInstalab

D-Arabinitol

Urine Test
An exploratory clue to Candida activity, studied mainly in serious infections.
4.8 (3,298 reviews)
Tested by Genova Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Self-collect at home
Kit shipped directly to you
Get results
Explained with clear next steps, no medical jargon

Should you take a D-Arabinitol test?

This test is most useful if any of these apply to you.

Investigating Persistent Digestive Symptoms
Understand the limits of an exploratory urine marker before attributing your symptoms to Candida.
Being Evaluated for a Serious Candida Infection
Hospital studies offer limited evidence for specialist use alongside established infection tests.
Reviewing an Unexpected Urine Result
Put a result in context without assuming that a higher value proves gut overgrowth or requires treatment.

About D-Arabinitol

Urinary D-arabinitol has been studied as a clue to invasive Candida infection, mainly in hospitalized people with cancer or weakened immune defenses. Some studies found useful early changes. Most measured the urine D-to-L arabinitol ratio, which differs from the creatinine-normalized D-arabinitol result reported here.

If you're investigating bloating or digestive symptoms after antibiotics, the evidence is much thinner. Available studies do not establish this result as a way to diagnose gut yeast overgrowth, determine whether Candida is causing your symptoms, or show that lowering the number improves your health. Its use for gut health and routine wellness screening remains exploratory.

Where the Number Comes From

Arabinitol exists in two mirror-image forms, D and L. Both occur in healthy human body fluids. Laboratory cultures show that Candida albicans, Candida tropicalis and Candida parapsilosis produce the D form. Its presence in urine is therefore compatible with Candida activity, but it isn't exclusive evidence of infection.

Candida glabrata and Candida krusei generally produce little or no D-arabinitol. These species are one reason an unremarkable result cannot rule out a Candida infection. Infections caused by species that produce it can also be missed.

This urine test reports D-arabinitol relative to creatinine. Creatinine is a waste product produced by muscle metabolism and excreted through the kidneys. Dividing by urine creatinine reduces the effect of how concentrated or dilute your sample is. It does not make the result independent of kidney function or changes in creatinine excretion.

The D-to-L ratio used in much of the hospital research divides D-arabinitol by L-arabinitol instead. Serum studies measure the compound in the liquid portion of blood. These measurements have different denominators or specimens, so their numerical results and diagnostic performance cannot be transferred directly to this urine test.

Evidence From Serious Candida Infections

Invasive candidiasis involves infection of the bloodstream or internal tissues. It can be life-threatening and occurs mainly in people with substantial risk factors, including intensive care admission, chemotherapy, central venous catheters and major abdominal surgery.

Several older studies evaluated repeated urine D-to-L ratios in people with blood cancers and very low counts of infection-fighting white blood cells. Their results were promising in some settings and poor in others.

Who Was StudiedMeasurementWhat Was Found
61 hospitalized adults with blood cancers, with an additional healthy comparison groupRepeated urine D-to-L arabinitol ratiosDetected 88% of confirmed disseminated infections; 91% of comparison participants without disseminated infection tested negative.
100 children with cancerRepeated urine D-to-L arabinitol ratiosDetected all 10 confirmed invasive infections in this small study. Positive results also occurred without confirmed infection.
104 adults with blood cancers receiving antifungals for unexplained feverUrine D-to-L arabinitol ratiosDetected only one of five bloodstream infections. Several brief bloodstream infections were missed, and positive results often appeared late.

These figures describe selected hospital populations and repeated testing with a different urine calculation. They are not accuracy estimates for a single creatinine-normalized result obtained during an outpatient gut-health evaluation.

Blood studies also found that performance depended on the population. A study measuring D-to-L ratios in serum detected about three quarters of bloodstream Candida infections in a subgroup with blood disorders and prolonged low white cell counts, but about four in ten across the broader study population. These serum findings cannot be used as detection rates for this urine test.

How Early Can It Change?

Blood cultures can miss invasive infections, particularly when infection is confined to internal tissues. That has driven research into additional fungal markers.

In the study of adults with blood cancers, 71% of those with subsequently confirmed disseminated infection already had an elevated urine D-to-L ratio when antifungal treatment began on suspicion. Confirmation followed the first elevated ratio by an average of about three weeks. Confirmation included culture or tissue findings, so this was not a three-week advantage over blood cultures in every case.

The later study that missed several bloodstream infections shows why this early-detection result cannot be treated as a dependable warning period. The studies also did not establish that using creatinine-normalized urinary D-arabinitol to guide care improves outcomes.

Does It Reflect Infection Severity?

A study of people with cancer and bloodstream Candida infection measured D-arabinitol relative to creatinine in serum. Death occurred in 71% of those with persistently elevated or increasing values, compared with 18% of those whose values resolved or were never elevated. This was an observational association in a small subgroup. It does not provide a prognosis from your urine result or show that lowering the marker itself reduces the risk of death.

Gut Yeast and Overgrowth

Candida can live in the digestive tract without causing disease. Finding it there does not establish that it explains bloating, abdominal discomfort or changes in bowel habits.

Research on small intestinal fungal overgrowth has used cultures of fluid collected directly from the small intestine. In one study of people with persistent digestive complaints, symptoms were similar whether or not bacterial or fungal overgrowth was found. Urinary D-arabinitol has not been established as a substitute for that evaluation.

There is no validated pattern in which a small urine elevation identifies gut overgrowth and a larger elevation identifies invasive infection. The result also cannot locate the source of the compound. A stool Candida result adds information about organisms present in stool, but it cannot by itself establish small intestinal overgrowth or show that yeast is causing your symptoms.

When Results Can Be Misleading

  • Urine concentration and kidney function: creatinine normalization reduces dilution effects, but interpretation still depends on reasonably stable creatinine excretion. Changing kidney function can complicate the comparison between samples.
  • Candida species: some species produce little or no D-arabinitol, and even infections involving producing species can be missed.
  • Different measurements: total arabinitol includes both D and L forms. Total arabinitol, D-arabinitol relative to creatinine, D-to-L ratios and serum measurements are not interchangeable. Differences in analytical methods and sample handling can also limit comparisons between laboratories.
  • Age: newborns can excrete substantial amounts of D-arabinitol and related sugar alcohols without Candida infection. Findings from adults cannot be applied directly to infants.
  • Rare metabolic disorders: high D-arabinitol together with other sugar alcohols has been reported in rare disorders of how the body processes these compounds. Yeast is not the only possible explanation.

What a Trend Can Show

Repeated testing can show whether the measured value is reproducible or changing. The size of a change that represents meaningful improvement in gut health has not been established. A personal baseline does not solve the uncertainty about what caused an elevation, and a falling result alone does not establish that an infection has cleared.

What Moves This Biomarker

Evidence-backed interventions that affect your D-Arabinitol level

↓ Decrease
Prescription antifungal therapy for invasive candidiasis
Successful treatment has been accompanied by falling urinary D-to-L arabinitol ratios, a related but different measurement. This supports a possible decrease during recovery, but the expected change in creatinine-normalized urinary D-arabinitol has not been established. The urine result cannot determine when treatment should stop.
MedicationModerate Evidence

Frequently Asked Questions

References

22 studies
  1. Bernard EM, Christiansen KJ, Tsang SF, Kiehn TE, Armstrong DJournal of Clinical Microbiology1981
  2. Bernard EM, Wong B, Armstrong DThe Journal of Infectious Diseases1985
  3. Lehtonen L, Anttila VJ, Ruutu T, Salonen J, Nikoskelainen J, Eerola E, Ruutu PJournal of Clinical Microbiology1996
  4. Salonen JH, Rimpiläinen MA, Lehtonen L, Lehtonen OP, Nikoskelainen JEuropean Journal of Clinical Microbiology & Infectious Diseases2001

D-Arabinitol Testing Options

$405

See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.

Includes 49 biomarkers:
D-Arabinitol3-Indoleacetic AcidPhenylacetic AcidDHPPA3-Hydroxyphenylacetic Acid
$509

A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.

90 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant